Revlimid is a thalidomide analogue indicated for the treatment of patients with Mantle Cell Lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib

Subtype:

Mantle Cell Lymphoma (MCL)

License:

FDA

Class:

Immunomodulatory agent

R/R

PIhttp://www.celgene.com/content/uploads/revlimid-pi.pdf 

  1. Approved Labelling

    Revlimid is a thalidomide analogue indicated for the treatment of patients with Mantle Cell Lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

  2. Treatment Regimen

    The recommended starting dose of Revlimid is 25 mg/day orally on Days 1-21 of repeated 28-day cycles for relapsed or refractory mantle cell lymphoma. Treatment should be continued until disease progression or unacceptable toxicity. Treatment is continued, modified or discontinued based upon clinical and laboratory findings.

  3. AE/Warnings

    Please see section 5 of the PI.

 

Disclaimer: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.